The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
June 7, 2017
Back to Press Releases
Therapeutic agents that treat serious conditions are eligible for the Food and Drug Administration (FDA) accelerated approval. A new study in the June issue of The Milbank Quarterly has found that these drugs often quickly become part of standard treatment, despite shortcomings in their evidence base. The study, the first to provide a systematic evaluation of all clinical studies conducted on drugs receiving this type of approval, assessed 37 novel therapeutic agents that received accelerated approval between 2000 and 2013.
